{"id":5311,"date":"2020-03-31T13:48:09","date_gmt":"2020-03-31T11:48:09","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/adivo-and-bayer-animal-health-unterzeichnen-globalen-kollaborationsvertrag\/"},"modified":"2020-06-29T11:22:47","modified_gmt":"2020-06-29T09:22:47","slug":"adivo-and-bayer-animal-health-unterzeichnen-globalen-kollaborationsvertrag","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/adivo-and-bayer-animal-health-unterzeichnen-globalen-kollaborationsvertrag\/","title":{"rendered":"adivo and Bayer Animal Health unterzeichnen globalen Kollaborationsvertrag"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

adivo and Bayer Animal Health sign global collaboration Agreement<\/span><\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]June 2019[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]adivo GmbH and Bayer Ani\u00admal Health GmbH have signed a global collaboration agreement to develop therapeutic antibodies for veterinary medicine. Under the terms of the agreement, Bayer Animal Health will have access to adivo\u2019s species-specific monoclonal antibody technology. Financial terms were not disclosed. adivo and Bayer Animal Health have agreed to jointly discover and develop species-specific therapeutic monoclonal antibodies that address the demand for innovative therapies for household pets. The companies aim to provide veterinarians with new and innovative treatments that address unmet medical needs of their animal patients. adivo will select species-specific antibodies using its proprietary fully canine phage display library. Bayer Animal Health will provide targets associated with severe animal \u00addiseases.
\n[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote”][vc_column_inner][vc_single_image image=”5327″ img_size=”155×155″ alignment=”center” style=”vc_box_circle_2″][vc_column_text el_class=”gco-magazine–picture-discription-blank”]Dr. Kathrin Ladetzki-\u00adBaehs,
\nDr. Markus Waldhuber,
\nManaging Directors, \u00adadivo GmbH[\/vc_column_text][vc_column_text el_class=”gco-magazine-copyright-blank”]<\/p>\n

\u00a9 adivo GmbH (2019)<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row css=”.vc_custom_1593422245634{margin-top: 45px !important;}”][vc_column]\n\n

\n \n